The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.

The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.

The present invention provides a composition for lipolysis, for example a pharmaceutical composition for preventing or treating obesity including localized fat deposits (LFD), comprising certain phosphocholine derivatives or pharmaceutically acceptable salt thereof. The pharmaceutical composition of the present invention shows an excellent lipolytic activity as well as a uniform lipolytic activity. And also, the pharmaceutical composition of the present invention can minimize side effects such as inflammation, tissue necrosis, etc., at the administered site. In addition, the pharmaceutical composition of the present invention has excellent storage stability.

The invention relates generally to cyclic peptides and their use in compositions, especially topical, cosmetic and/or personal care compositions, and compositions containing said cyclic peptides.

It is an object of the present disclosure to provide a formulation for injectable collagenase which will have extended residence time for the drug at the therapeutic targeted area for the indication being treated. It is a further object of the disclosure to provide a slow release formulation for collagenase which is compatible with the active ingredient and does not adversely affect its activity. Still a further object of the disclosure is to provide an injectable formulation for collagenase which can be effectively administered to a patient with a small size needle without exhibiting pregelation, which would interfere with the ability to deliver the required dose for treatment.

It is an object of the present disclosure to provide a formulation for injectable collagenase which will have extended residence time for the drug at the therapeutic targeted area for the indication being treated. It is a further object of the disclosure to provide a slow release formulation for collagenase which is compatible with the active ingredient and does not adversely affect its activity. Still a further object of the disclosure is to provide an injectable formulation for collagenase which can be effectively administered to a patient with a small size needle without exhibiting pregelation, which would interfere with the ability to deliver the required dose for treatment.

Provided are cosmetic compositions comprising a silicone acrylate copolymer, a polypropylsilsesquioxane film forming resin, a hydrocarbon-based resin, a non-volatile oil, a volatile hydrocarbon solvent, and optionally a wax, wherein the ratio of the silicone acrylate copolymer to the polypropylsilsesquioxane resin is from about 1:1 to about 4:1, the weight percent ratio of silicone acrylate copolymer plus the polypropylsilsesquioxane film forming resin to the at least one hydrocarbon-based resin is from about 1.5:1 to about 30:1 on a dry weight basis, and the total amount of the polypropyl silsesquioxane film forming resin and the silicone acrylate copolymer is greater than about 10% on a dry weight basis relative to the weight of the composition.

Provided are cosmetic compositions comprising a silicone acrylate copolymer, a polypropylsilsesquioxane film forming resin, a hydrocarbon-based resin, a non-volatile oil, a volatile hydrocarbon solvent, and optionally a wax, wherein the ratio of the silicone acrylate copolymer to the polypropylsilsesquioxane resin is from about 1:1 to about 4:1, the weight percent ratio of silicone acrylate copolymer plus the polypropylsilsesquioxane film forming resin to the at least one hydrocarbon-based resin is from about 1.5:1 to about 30:1 on a dry weight basis, and the total amount of the polypropyl silsesquioxane film forming resin and the silicone acrylate copolymer is greater than about 10% on a dry weight basis relative to the weight of the composition.

Suggested are new extracts of microalgae selected from the group consisting of (i) Monodus sp. (ii) Thalassiosira sp. (iii) Chaetoceros sp. and/or (iv) Chlorococcum sp.
obtainable by treating said microalgae with a solvent selected from the group consisting of C.sub.1-C.sub.4 aliphatic alcohols, ethyl acetate, water or their mixtures, removing the dissolved extracts from the residues and recovering the pure extracts from the solvent. The extracts show excellent properties particularly in modulating the metabolism of human skin and hair follicles.

The invention provides fused heterocyclic organic compounds such as dihydropyrazolopyridotriazinones, compositions containing such compounds, medical kits, and methods for using such compounds and compositions for body contouring and/or reduction of fat in a subject.